Howard E Gendelman Selected Research

sargramostim (Leukine)

1/2022	Monocyte biomarkers define sargramostim treatment outcomes for Parkinson's disease.
5/2021	Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease.
1/2017	Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Howard E Gendelman Research Topics

Disease

45	Infections 01/2022 - 12/2002
35	Parkinson Disease (Parkinson's Disease) 01/2022 - 06/2004
20	Dementia (Dementias) 01/2018 - 03/2002
18	Neurodegenerative Diseases (Neurodegenerative Disease) 02/2022 - 03/2002
15	Alzheimer Disease (Alzheimer's Disease) 12/2021 - 08/2004
14	Virus Diseases (Viral Diseases) 01/2022 - 12/2002
14	Encephalitis (Encephalitis, Rasmussen) 09/2010 - 12/2002
12	Neuroinflammatory Diseases 11/2021 - 01/2007
11	Cognitive Dysfunction 11/2021 - 08/2002
10	HIV Infections (HIV Infection) 03/2020 - 02/2007
10	Neurocognitive Disorders (Clerambault Syndrome) 11/2014 - 08/2008
8	Disease Progression 04/2013 - 01/2007
7	Inflammation (Inflammations) 01/2022 - 10/2003
5	Drug-Related Side Effects and Adverse Reactions 11/2019 - 11/2012
5	Acquired Immunodeficiency Syndrome (AIDS) 01/2018 - 01/2004
4	Amyloidosis 05/2018 - 05/2009
4	Nervous System Diseases (Neurological Disorders) 04/2015 - 09/2005
3	Injection Site Reaction 01/2022 - 01/2018
3	Central Nervous System Diseases (CNS Diseases) 01/2019 - 04/2007
3	Gliosis 01/2016 - 06/2004
3	Persistent Infection 12/2013 - 08/2002
2	Communicable Diseases (Infectious Diseases) 02/2022 - 01/2017
2	COVID-19 01/2022 - 11/2021
2	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 11/2021 - 01/2021
2	Body Weight (Weight, Body) 01/2020 - 01/2018
2	Visceral Leishmaniasis (Kala Azar) 01/2018 - 01/2017
2	Mitochondrial Diseases (Mitochondrial Disease) 03/2010 - 01/2007
2	Brain Diseases (Brain Disorder) 01/2010 - 05/2003
2	Amyloid Plaque 05/2009 - 02/2007
2	Necrosis 01/2009 - 07/2008
2	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 09/2008 - 01/2007
1	Poliomyelitis (Polio) 01/2022
1	Tremor (Tremors) 01/2022
1	Measles 01/2022
1	Hepatitis C 01/2022
1	Mpox (monkeypox) 01/2022
1	Smallpox (Variola) 01/2022
1	Movement Disorders (Movement Disorder) 05/2021

Drug/Important Bio-Agent (IBA)

23	Pharmaceutical PreparationsIBA 01/2022 - 02/2007
19	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2004
12	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 01/2018 - 06/2004
11	Biomarkers (Surrogate Marker)IBA 01/2022 - 03/2007
9	Antiviral Agents (Antivirals)IBA 01/2022 - 02/2004
7	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2022 - 01/2015
6	VaccinesIBA 01/2022 - 12/2002
6	NeurotoxinsIBA 01/2007 - 08/2002
5	Amyloid (Amyloid Fibrils)IBA 11/2021 - 05/2009
5	EnzymesIBA 01/2021 - 12/2006
5	CatalaseIBA 07/2014 - 01/2011
5	AntioxidantsIBA 01/2013 - 09/2007
4	CytokinesIBA 01/2022 - 06/2004
4	AntigensIBA 01/2014 - 08/2006
4	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2012 - 12/2006
4	ProteomeIBA 01/2012 - 04/2007
4	alpha-SynucleinIBA 03/2010 - 01/2007
3	sargramostim (Leukine)FDA Link 01/2022 - 01/2017
3	Peptides (Polypeptides)IBA 01/2020 - 11/2007
3	Presenilin-1IBA 10/2015 - 05/2009
3	Blood Proteins (Serum Proteins)IBA 09/2015 - 09/2010
3	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 09/2013 - 05/2003
3	TEMPOIBA 04/2009 - 08/2006
2	ProdrugsIBA 02/2022 - 03/2020
2	EpitopesIBA 12/2021 - 03/2010
2	DNA (Deoxyribonucleic Acid)IBA 12/2021 - 01/2013
2	AutoantigensIBA 11/2021 - 12/2002
2	Messenger RNA (mRNA)IBA 01/2021 - 02/2003
2	Amyloid beta-PeptidesIBA 01/2020 - 05/2009
2	Biological ProductsIBA 01/2020 - 07/2012
2	Amphotericin B (Amphotericin)FDA LinkGeneric 01/2018 - 01/2017
2	Cathepsin BIBA 01/2017 - 01/2009
2	ManganeseIBA 01/2016 - 01/2016
2	Type II Vasoactive Intestinal Peptide ReceptorsIBA 01/2016 - 12/2015
2	Folic Acid (Vitamin M)FDA LinkGeneric 08/2015 - 11/2013
2	PolymersIBA 03/2014 - 05/2007
2	3,9-bis((ethylthio)methyl)-K-252aIBA 06/2013 - 01/2010
2	Phosphotransferases (Kinase)IBA 06/2013 - 01/2010
2	Platelet Activating FactorIBA 08/2009 - 12/2002
2	LithiumIBA 04/2009 - 09/2005
2	Glatiramer Acetate (Copaxone)FDA Link 09/2008 - 04/2007
2	Coat Protein Complex I (COPI)IBA 11/2007 - 10/2007
2	Glycogen Synthase Kinase 3 betaIBA 03/2007 - 01/2004
2	Valproic Acid (Depakote)FDA LinkGeneric 03/2007 - 10/2003
2	Neuroprotective AgentsIBA 09/2005 - 08/2004
2	ChemokinesIBA 05/2003 - 03/2002
1	ceric oxide (cerium dioxide)IBA 01/2022
1	smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordicIBA 01/2022
1	Hepatitis B Vaccines (Hepatitis B Vaccine)IBA 01/2022
1	Synthetic Vaccines (Recombinant Vaccines)IBA 01/2022
1	Smallpox Vaccine (Vaccine, Smallpox)FDA Link 01/2022
1	sarkosylIBA 12/2021
1	Immunologic Factors (Immunomodulators)IBA 11/2021
1	Amyloidogenic ProteinsIBA 11/2021
1	dolutegravirIBA 11/2021

Therapy/Procedure

35	Therapeutics 02/2022 - 08/2002
16	Art Therapy 01/2021 - 02/2007
5	Highly Active Antiretroviral Therapy (HAART) 06/2012 - 01/2004
3	Drug Therapy (Chemotherapy) 01/2018 - 05/2010
2	Intramuscular Injections 01/2020 - 01/2018
2	Immunotherapy 01/2020 - 12/2011
2	Precision Medicine 01/2019 - 01/2017